Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Treasury Shares (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Treasury Shares for 3 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 100.0% to $8.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.0 million, a 100.0% increase, with the full-year FY2025 number at $8.0 million, up 100.0% from a year prior.
  • Treasury Shares was $200000.0 for Q4 2025 at Ultragenyx Pharmaceutical, up from $173034.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $200000.0 in Q4 2025 to a low of $7812.0 in Q1 2023.
  • A 3-year average of $86686.0 and a median of $66993.0 in 2024 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: soared 835.96% in 2024, then skyrocketed 100.0% in 2025.
  • Ultragenyx Pharmaceutical's Treasury Shares stood at $432000.0 in 2023, then soared by 825.93% to $4.0 million in 2024, then surged by 100.0% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Treasury Shares are $8.0 million (Q4 2025), $8.0 million (Q3 2025), and $8.0 million (Q2 2025).